Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00872300 · ClinicalTrials.gov registry record · Phase 2
PHA-739358 for the Treatment of Multiple Myeloma
A Phase 2 study, sponsored by Nerviano Medical Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT00872300 is a Phase 2 study that was terminated before completion, run by Nerviano Medical Sciences. The registered enrollment target is 7 participants.
The verdict
NCT00872300, a Phase 2 study, was terminated before completion, sponsored by Nerviano Medical Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the antitumor activity of PHA-739358 as single agent IV infusion in adult patients with Multiple Myeloma who have a history of at least 2 previous lines of treatment for the disease.
Interventions
- DRUG PHA-739358
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2008-10 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00872300
The ClinicalTrials.gov registry entry for NCT00872300 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nerviano Medical Sciences, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PHA-739358 is the first listed.
NCT00872300 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00872300 about?
NCT00872300 is a clinical study titled "PHA-739358 for the Treatment of Multiple Myeloma". The purpose of this study is to determine the antitumor activity of PHA-739358 as single agent IV infusion in adult patients with Multiple Myeloma who have a history of at least 2 previous lines of treatment for the disease.
What is the current status of trial NCT00872300?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2008-10. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00872300?
The interventions under investigation include: PHA-739358 (DRUG).
Who is sponsoring clinical trial NCT00872300?
This trial is sponsored by Nerviano Medical Sciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.